HNF4A and adrenal cortex carcinoma: In adrenocortical cancer, PNU-74654 treatment prevented the binding of TCF to β-catenin and decreased CTNNB1 mRNA expression and nuclear β-catenin accumulation, thereby promoting apoptosis cells, reducing cell viability, and impairing adrenal steroid secretion [21].